Gynaecologic Oncology Society of Kenya (GOSK) clinical management protocol for gestational trophoblastic neoplasia (GTN) in Kenya - 2026
DOI:
https://doi.org/10.59692/9y13c356Keywords:
Gestational trophoblastic neoplasia, Gestational trophoblastic disease, Hydatidiform mole, KenyaAbstract
Objective: To establish a standardized, evidence-based approach to the management of gestational trophoblastic neoplasia (GTN) in Kenya.
Methods: This protocol was developed using a guideline adaptation approach, drawing on high-quality international clinical practice guidelines and contextualizing their recommendations to Kenya’s health care system and available resources. A multidisciplinary panel comprising gynecologic oncologists, pathologists, radiologists, oncology nurses, pharmacists, radiation oncologists, public health specialists, and patient representatives contributed to the process. Panel members received technical training from experts at the University of Nairobi and Kenyatta National Hospital on evidence-based guideline adaptation, including standardized appraisal, systematic evaluation of guidelines, and contextualization to local needs. A systematic literature search was conducted in PubMed and Google Scholar. Six guidelines were identified and independently appraised using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument. Four guidelines were selected for adaptation: the National Comprehensive Cancer Network (NCCN) Guidelines for Gestational Trophoblastic Neoplasia (2025); the International Federation of Gynecology and Obstetrics (FIGO) 2021 update on the diagnosis and management of gestational trophoblastic disease; the European Organization for Treatment of Trophoblastic Diseases (EOTTD) Practical Clinical Guidelines for Treatment and Referral of Gestational Trophoblastic Disease (2020); and the Society of Obstetricians and Gynaecologists of Canada (SOGC) Guideline No. 408: Management of Gestational Trophoblastic Diseases (2021). Recommendations from these guidelines were reviewed and contextualized to Kenya’s health care infrastructure and resource setting.
Results: The protocol provides recommendations for the diagnosis, risk stratification, treatment, and follow-up of GTN. Diagnosis is based on the FIGO criteria, while the WHO-modified scoring system is used to classify patients into low-risk and high-risk categories. The protocol also identifies an ultra-high-risk group requiring specific treatment considerations. Single-agent chemotherapy is recommended for appropriately selected patients with low-risk GTN, whereas multi-agent chemotherapy is recommended for high-risk and ultra-high-risk disease. Surgery is a principal component of management for placental site trophoblastic tumor (PSTT) and epithelioid trophoblastic tumor (ETT). The protocol also addresses the management of recurrent disease, post-treatment surveillance, fertility and reproductive health considerations, and supportive and palliative care.
Recommendations: This protocol provides a standardized framework for the evidence-informed management of GTN in Kenya. It is intended to support consistent clinical decision-making, multidisciplinary care, appropriate use of available resources, and improved patient outcomes.
References
1. Horowitz NS, Eskander RN, Adelman M.R, Burke W. Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidence-based review and recommendation. Gynecologic Oncology 163 (2021) 605–613.
2. Ahmed Zakaria, Reda Hemida, Waleed Elrefaie, Ehsan Refaie. Incidence and outcome of gestational trophoblastic disease in lower Egypt. African Health Sciences Vol 20 Issue 1, March, 2020.
3. Amina R. Hassan, Peter M. Itsura, Barry P. Rosen, Allan L. Covens, Afrin F. Shaffi, Elly B. Odongo, Anisa W. Mburu, Wilmot L. Smith, Sharon K. Moturi, Ronald K. Too, Chia M. Ayeah, Philip K. Tonui. Mortality factors in high and ultra-high-risk gestational trophoblastic neoplasia at Moi teaching & referral hospital: A decade-long observation in Kenya. Gynecol Oncol Rep. 2024 Jun; 53: 101392. Published online 2024 Apr 16. doi: 10.1016/j.gore.2024.101392
4. Hertig AT, Mansell H. Tumors of the female sex organs. Part 1. Hydatidiform mole and choriocarcinoma. In: Atlas of Tumor Pathology (1st series), Armed Forces Institute of Pathology, Washington, DC 1956. Fascicle 33.
5. Goldstein DP, Berkowitz RS. Gestational Trophoblastic Neoplasms: Clinical Principles of Diagnosis and Management, WB Saunders, Philadelphia, 1982.
6. Deleuze Antoine, Christophe Massard , Fanny Le Du , Benoit You , Claudia Lefeuvre-Plesse , Pierre-Adrien Bolze , Thibault de la Motte Rouge. Management of trophoblastic tumors: review of evidence, current practice, and future directions. Expert Review of Anticancer Therapy Volume 23, 2023 - Issue 7 2023 Jul;23(7):699-708. doi: 10.1080/14737140.2023.2215438. Epub 2023 May 22.
7. Ansar Hussain Ansar, Aziz Shiekh Aejaz, Mohd Bhat Gul, Lone AR. Gestational trophoblastic neoplasia, management as per risk stratification in a developing country. Indian Journal of Medical and Pediatric Oncology. 2016.
8. Alimena S, Elias KM, Horowitz NS, Berkowitz RS. Hematol Oncol Clin North Am. 2024;38(6):1233. Epub 2024 Sep 25
9. Ngan H Y S, Michael J. Seckl, Ross S. Berkowitz, Yang Xiang, François Golfier, Paradan K. Sekharan, John R. Lurain, Leon Massuger. Diagnosis and management of gestational trophoblastic disease: 2021 update Figo Cancer Report 2 0 21. First published: 20 October 2021 https://doi.org/10.1002/ijgo.13877
10. Singh N, Singh U, Srivastava S. Prospective and Retrospective Analysis of Gestational Trophoblastic Disease over a Period of 5 Years. Journal of South Asian Federation of Obstetrics and Gynecology, January-April 2013;5(1):11-14.
11. Mburu A, Tonui P, Keitany K, Osborne R. The pregnancy that wasn’t: challenges of gestational trophoblastic neoplasia management in low- and middle-income countries. International Journal of Gynecological Cancer. Vol 32. Issue 7. July 2022.
12. National Cancer Comprehensive Network (NCCN) Clinical Practice Guidelines in Oncology: Gestational Trophoblastic Neoplasia. NCCN. 2025.
13. Management Of Gestational Trophoblastic Disease. Green-Top Guideline No. 38. Royal College of Obstetricians and Gynecologists (RCOG). 2020.
14. Practical clinical guidelines of the European Organization for the Treatment of Trophoblastic Disease (EOTTD) for treatment and referral of gestational trophoblastic disease (2020). European Organization for the Treatment of Trophoblastic Disease. 2020.
15. Guideline No. 408: Management Of Gestational Trophoblastic Diseases. Society of Obstetricians and Gynecologists of Canada (SOGC). 2021.
16. Management Of Gestational Trophoblastic Disease (2020). Royal Australian and New Zealand College of Obstetrician/Gynecologists (RANZOG). 2020.
17. World Health Organization. Medical eligibility criteria for contraceptive use.6th ed. Geneva. World Health Organization. 2025.
18. Kenya Palliative Care Policy 2021-2030. Kenya. 2021.
19. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 6.0. Bethesda (MD): U.S. Department of Health and Human Services, National Institutes of Health; 2025.
Published
Issue
Section
License
Copyright (c) 2026 Dr. Gideon M. Mutua, Dr. Margaret K. Kilonzo, Prof. Eunice J. Cheserem, Dr. Alfred Mokomba, Dr. Wycliffe Musalia, Dr. Millicent S. Masinde, Dr. Benjamin E. Odongo, Prof. Jacqueline J. Chesang', Dr. Victor T. Otieno, Dr. Francis O. Abinya, Dr. Isaac M. Maingi, Dr. Bruce O. Semo, Dr. Innocent O. Maranga, Dr. Yusuph Mwidibo, Dr. Naomi N. Sitati, Dr. Anwar Z. Mohamed, Dr. Stella N. Njenga, Dr. Diana Marion, Dr. Simon M. Gitau, Dr. Steven M. Ibua, Prof. Rose J. Kosgei

This work is licensed under a Creative Commons Attribution 4.0 International License.
